Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 1,121–1,140 of 18,047 drug recalls

Drug Recall Ongoing Historical recordClass II

Acetaminophen Tablets, 325 mg, 100-count bottles, Distributed by: Amazon.com Services LLC, 410 Terry Avenue N., Seattle, WA 98109, NDC 72288-405-10

by Aurobindo Pharma USA Inc

Reason
cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).
Recall initiated
May 22, 2025
Reported by FDA
June 25, 2025
Distribution
USA Nationwide.

View recall →

Drug Recall Ongoing Historical recordClass II

Icosapent Ethyl Capsules 1 gram, 120 Capsules per Bottle, Rx Only, Manufactured by Doppel Farmaceutici s.r.l., Piacenza, Italy, Distributed by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1592-7.

by Zydus Pharmaceuticals (USA) Inc

Reason
Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage of capsule contents.
Recall initiated
May 30, 2025
Reported by FDA
June 18, 2025
Distribution
IL, PA, & MS

View recall →

Drug Recall Ongoing Historical recordClass I

Sulfamethoxazole and Trimethoprim Tablets, USP, 400 mg/80 mg, Rx Only, a) 100 Tablets per Bottle, NDC: 65162-271-10, b) 500 Tablets per Bottle, NDC: 65162-271-50, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad, 382213, INDIA, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807.

by Amneal Pharmaceuticals, LLC

Reason
Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination.
Recall initiated
June 2, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass III

Levothyroxine Sodium Tablets, USP 112 mcg (0.112mg), 1000 tablets, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540. Manufactured by: Macleods Pharmaceuticals Ltd. Sarigam, Valsad, Gujarat, India, NDC 33342-398-44.

by Macleods Pharmaceuticals Ltd

Reason
Presence of a foreign substance: black hair found embedded in tablet.
Recall initiated
May 29, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 200 mL (when mixed), Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascent Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-544-68

by Ascend Laboratories, LLC

Reason
Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.
Recall initiated
May 23, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed), Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascent Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-544-88

by Ascend Laboratories, LLC

Reason
Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.
Recall initiated
May 23, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass I

Male Ultra Pro, Unleash Your Force 2, 10 capsules per box, Distributed by: Health Fixer Tempe AZ 85288, UPC B0CZN7C6YH.

by SAINI TRADE INC

Reason
Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.
Recall initiated
April 14, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass I

ULTRA ARMOR, My Armor My Power, Dietary Supplement, 10 capsules per box, Distributed by Health Fixer, Tempe, AZ 85288, UPC B0CYJ7Y5H9.

by SAINI TRADE INC

Reason
Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.
Recall initiated
April 14, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass I

ELECTRO BUZZ, Dietary Supplement, 10 capsules per box, Distributed By: Health Fixer, Tempe, AZ 85288, UPC B0DK68LF6J.

by SAINI TRADE INC

Reason
Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared chloropretadalafil, propoxyphenylsildenafil, and sildenafil.
Recall initiated
April 14, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass I

MALEXTRA, Recharge with Extra, Dietary Supplement, 10 capsules per box, Distributed by: Health Fixer, Tempe, AZ 85288, UPC B0CWKZ6ZP3.

by SAINI TRADE INC

Reason
Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.
Recall initiated
April 14, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass I

Male Ultra, Unleash Your Force, Dietary Supplement,10 capsules per box, Distributed By; Health Fixer, Tempe, AZ 85288, UPC B0CMQ4FTHG.

by SAINI TRADE INC

Reason
Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.
Recall initiated
April 14, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass III

Ezetimibe and Simvastatin Tablets, 10mg/40mg, 90-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Madya Pradesh, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-323-90

by Glenmark Pharmaceuticals Inc., USA

Reason
Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.
Recall initiated
May 19, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide USA and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Chlorthalidone Tablets, USP, 25 mg, 50 Tablets (5x10) Unit Dose cards per carton, Rx only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-167-15

by AvKARE

Reason
Failed Dissolution Specifications
Recall initiated
May 9, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide USA

View recall →

Drug Recall Ongoing Historical recordClass II

Celecoxib Capsules, 200 mg, 50 Capsules (5x10) Unit Dose per carton, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478. NDC 50268-169-15

by AvKARE

Reason
Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules
Recall initiated
May 13, 2025
Reported by FDA
June 18, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

Celecoxib Capsules, 200 mg, 500-count bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division), Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-142-71

by Alembic Pharmaceuticals Limited

Reason
Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule
Recall initiated
May 9, 2025
Reported by FDA
June 18, 2025
Distribution
Distributed Nationwide and in PR

View recall →

Drug Recall Ongoing Historical recordClass II

Spectrum Advanced Gel Hand Sanitizer, Ethyl alcohol 70%, 8 FL OZ (236 mL) per bottle, Manufactured for Medline Industries, Inc., Three Lakes Drive, Northfield, IL 60693 USA. NDC: 53329-202-08, UPC 8 88277 34945 5

by Consumer Product Partners, LLC

Reason
Subpotent product: Product has cloudy appearance and tested below assay label claim for 70% Ethyl Alcohol
Recall initiated
May 23, 2025
Reported by FDA
June 11, 2025
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Lacosamide Oral Solution, USP, 10 mg/mL, 200 mL, Rx Only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston FL 33326, NDC 60505-0405-4

by Apotex Corp.

Reason
Defective Container: This recall is being initiated due to a leaking unit stored horizontally.
Recall initiated
May 28, 2025
Reported by FDA
June 11, 2025
Distribution
US Nationwide.

View recall →

Drug Recall Completed Historical recordClass II

Fluoxetine Tablets, USP, 20 mg, 28-count Carton (4x7 Unit-dose), Manufactured by: TORRENT PHARMACEUTIALS LTD., Indrad-382 721 INDIA; Manufactured for: TORRENT PHARMA INC., Basking Ridge, NJ 07920. NDC: 13668-473-91 (Carton); 13668-473-70 (Blister)

by Torrent Pharma Inc.

Reason
CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.
Recall initiated
May 27, 2025
Reported by FDA
June 11, 2025
Distribution
U.S. Nationwide.

View recall →

Drug Recall Completed Historical recordClass II

Fluoxetine Tablets, USP, 20 mg, 30-count bottle, Rx only, Manufactured by: TORRENT PHARMACEUTIALS LTD., Indrad-382 721 INDIA; Manufactured for: TORRENT PHARMA INC., Basking Ridge, NJ 07920. NDC: 13668-473-30

by Torrent Pharma Inc.

Reason
CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.
Recall initiated
May 27, 2025
Reported by FDA
June 11, 2025
Distribution
U.S. Nationwide.

View recall →

Drug Recall Ongoing Historical recordClass II

Indomethacin Extended-Release Capsules, USP, 75 mg, 30 capsules (3 x 10 blister cards) per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 68084-411-21 (carton), NDC 68084-411-11 (blister card).

by Amerisource Health Services LLC

Reason
cGMP deviations
Recall initiated
May 15, 2025
Reported by FDA
June 11, 2025
Distribution
Nationwide in the USA

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.

Reconnecting to the server…

We lost the connection to the server.

Your session has expired.